Enhanced dermal delivery of acyclovir using solid lipid nanoparticles

Drug Delivery and Translational Research

Volumn 1, Issue 5, 2011, Pages 395-406

  Jain, Sanyog ^a   Mistry, Meghal A ^a   Swarnakar, Nitin K ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Atomic force microscopy (AFM); CLSM; Dermal delivery; HSV infection; Solid lipid nanoparticles (SLNs)

Indexed keywords

ACICLOVIR; CALCEIN; DRUG CARRIER; EPIKURON 200; GLYCEROL BEHENATE; PHOSPHATIDYLCHOLINE; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CADAVER; CONFOCAL LASER MICROSCOPY; CREAM; DERMIS; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; EMULSION; ENCAPSULATION; EPIDERMIS; FEASIBILITY STUDY; HERPES SIMPLEX; HISTOLOGY; HUMAN; HUMAN TISSUE; HYDROPHILICITY; IN VITRO STUDY; MORPHOLOGY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RAT; SKIN PERMEABILITY; SKIN WATER LOSS; SPRAGUE DAWLEY RAT; STRATUM CORNEUM; X RAY POWDER DIFFRACTION;

EID: 84862991437     PISSN: 2190393X     EISSN: 21903948     Source Type: Journal    
DOI: 10.1007/s13346-011-0036-0     Document Type: Article

References (49)

1. Fleming DT, McQuillan GM, Johnson RE, Nahmias AJ, Aral SO, Lee FK, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J MED. 1997; 337(16): 1105.
2. Centers for Disease Control and Prevention (2010). Available at: http://www. cdc. gov/std/Herpes/STDFact-Herpes. htm. Accessed 10 June 2010.
3. Kleymann G. Helicase primase: targeting the Achilles heel of herpes simplex viruses. Antiviral Chem Chemother. 2004; 15(3): 135-40.
4. Boon R. Antiviral treatment: from concept to reality. Antiviral Chem Chemother. 1997; 8: 5-10.
5. Darby G. A history of antiherpes research. Antiviral Chem Chemother. 1994; 5: 3-9.
6. Parry GE, Dunn P, Shah VP, Pershing LK. Acyclovir bioavailability in human skin. J Invest Dermatol. 1992; 98(6): 856-63.
7. Freeman DJ, Sheth NV, Spruance SL. Failure of topical acyclovir in ointment to penetrate human skin. Antimicrob Agents Chemother. 1986; 29(5): 730-2.
8. Duncan JI, Wakeel RA, Winfield AJ, Ormerod AD, Thomson AW. Immunomodulation of psoriasis with a topical cyclosporin A formulation. Acta Derm Venereol. 1993; 73(2): 84-7.
9. Wang S, Kara M, Krishnan TR. Transdermal delivery of cyclosporin-A using electroporation. J Control Release. 1998; 50: 61-70.
10. Boinpally RR, Zhou SL, Devraj G, Anne PK, Poondru S, Jasti BR. Iontophoresis of lecithin vesicles of cyclosporin A. Int J Pharm. 2004; 274(1-2): 185-90.
11. Liu H, Li S, Pan W, Wang Y, Han F, Yao H. Investigation into the potential of low-frequency ultrasound facilitated topical delivery of cyclosporin A. Int J Pharm. 2006; 326(1-2): 32-8.
12. Gajardo J, Villaseca J. Psoriasis and cyclosporine: an attempt at topical treatment. Rev Med Chil. 1994; 122(12): 1404-7.
13. Shim J, Seok Kang H, Park WS, Han SH, Kim J, Chang IS. Transdermal delivery of mixnoxidil with block copolymer nanoparticles. J Control Release. 2004; 97(3): 477-84.
14. Wissing SA, Muller RH. Cosmetic applications for solid lipid nanoparticles (SLN). Int J Pharm. 2003; 254(1): 65-8.
15. Dingler A, Krohs S, Lukowski G, Gohla S, Muller RH. SLN (solid lipid nanoparticles) as new solid carrier of active ingredients in cosmetics. Eur J Pharm Sci. 1996; 4(1): S148-121.
16. Wissing SA, Muller RH. The influence of solid lipid nanoparticles on skin hydration and viscoelasticity-in vivo study. Eur J Pharm Biopharm. 2003; 56(1): 67-72.
17. Dingler A, Runge S, Muller RH. SLN (solid lipid nanoparticles) as drug carrier for an IV administration of poorly water soluble drugs. Eur J Pharm Sci. 1996; 4(1): S132-121.
18. Shah KA, Date AA, Joshi MD, Patravale VB. Solid lipid nanoparticles (SLN) of tretinoin: potential in topical delivery. Int J Pharm. 2007; 345(1-2): 163-71.
19. Yuan H, Jiang SP, Du YZ, Miao J, Zhang XG, Hu FQ. Strategic approaches for improving entrapment of hydrophilic peptide drugs by lipid nanoparticles. Colloids Surf B Biointerfaces. 2009; 70(2): 248-53.
20. Huidobro AL, Ruperez FJ, Barbas C. LC methods for acyclovir and related impurities determination. J Pharm Biomed Anal. 2005; 37(4): 687-94.
21. Panchagnula R, Patel JR. Transdermal delivery of azidothymidine (AZT) through rat skin ex-vivo. Pharma Sci. 1997; 3: 83-7.
22. Nair VB, Panchagnula R. The effect of pretreatment with terpenes on transdermal iontophoretic delivery of arginine vasopressin. Il Farmaco. 2004; 59(7): 575-81.
23. Panchagnula R, Bokalial R, Sharma P, Khandavilli S. Transdermal delivery of naloxone: skin permeation, pharmacokinetic, irritancy and stability studies. Int J Pharm. 2005; 293(1-2): 213-23.
24. Herkenne C, Naik A, Kalia YN, Hadgraft J, Guy RH. Dermatopharmacokinetic prediction of topical drug bioavailability in vivo. J Invest Dermatol. 2006; 127(4): 887-94.
25. Alvarez-Roman R, Naik A, Kalia YN, Guy RH, Fessi H. Enhancement of topical delivery from biodegradable nanoparticles. Pharma Res. 2004; 21(10): 1818-25.
26. Escobar-Chavez JJ, Merino-Sanjuán V, López-Cervantes M, Urban-Morlan Z, Piñón-Segundo E, Quintanar-Guerrero D, et al. The tape-stripping technique as a method for drug quantification in skin. J Pharm Pharm Sci. 2008; 11(1): 104.
27. Alvarez-Roman R, Naik A, Kalia YN, Guy RH, Fessi H. Skin penetration and distribution of polymeric nanoparticles. J Control Release. 2004; 99(1): 53-62.
28. Lashmar UT, Hadgraft J, Thomas N. Topical application of penetration enhancers to the skin of nude mice: a histopathological study. J Pharm Pharmacol. 1989; 41(2): 118-22.
29. Jain S, Mittal A, Jain AK. Enhanced topical delivery of cyclosporin-A using PLGA nanoparticles as carrier. Curr Nanosci. 2011; 7(4): 524-30.
30. Dingler A, Freie Universität B. Feste Lipid-nanopartikel als kolloidale Wirkstoffträgersysteme zur dermalen Applikation: Freie Universität Berlin; 1998.
31. Jain S, Chaudhari BH, Swarnakar NK. Preparation and characterization of niosomal gel for iontophoresis mediated transdermal delivery of isosorbide dinitrate. Drug Deliv and Transl Res. 2011; 1(4): 309-21.
32. Friedrich I, Muller-Goymann CC. Characterization of solidified reverse micellar solutions (SRMS) and production development of SRMS-based nanosuspensions. Eur J Pharm Biopharm. 2003; 56(1): 111-9.
33. You J, Wan F, de Cui F, Sun Y, Du Y-Z, Hu Fq. Preparation and characteristic of vinorelbine bitartrate-loaded solid lipid nanoparticles. Int J Pharm. 2007; 343(1-2): 270-6.
34. Heiati H, Phillips NC, Tawashi R. Evidence for phospholipid bilayer formation in solid lipid nanoparticles formulated with phospholipid and triglyceride. Pharma Res. 1996; 13(9): 1406-10.
35. Westesen K, Siekmann B. Investigation of the gel formation of phospholipid-stabilized solid lipid nanoparticles. Int J Pharm. 1997; 151(1): 35-45.
36. Rawat MK, Jain A, Mishra A, Muthu MS, Singh S. Development of repaglinide loaded solid lipid nanocarrier: selection of fabrication method. Curr Drug Deliv. 2010; 7(1): 44-50.
37. Dubes A, Parrot-Lopez H, Abdelwahed W, Degobert G, Fessi H, Shahgaldian P, et al. Scanning electron microscopy and atomic force microscopy imaging of solid lipid nanoparticles derived from amphiphilic cyclodextrins. Eur J Pharm Biopharm. 2003; 55(3): 279-82.
38. Kamel AO, Awad GA, Geneidi AS, Mortada ND. Preparation and characterization of acyclovir nanoparticles by double emulsion technique. Egypt J Biomed Sci. 2007; 23: 218-36.
39. Morissette SL, Almarsson O, Peterson ML, Remenar JF, Read MJ, Lemmo AV, et al. High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids. Adv Drug Deliv Rev. 2004; 56(3): 275-300.
40. Lv Q, Yu A, Xi Y, Li H, Song Z, Cui J, et al. Development and evaluation of penciclovir-loaded solid lipid nanoparticles for topical delivery. Int J Pharm. 2009; 372(1-2): 191-8.
41. Godin B, Touitou E. Transdermal skin delivery: Predictions for humans from in vivo, ex vivo and animal models. Adv Drug Deliv Rev. 2007; 59(11): 1152-61.
42. Cevc G. Lipid vesicles and other colloids as drug carriers on the skin. Adv Drug Deliv Rev. 2004; 56(5): 675-711.
43. Schafer-Korting M, Mehnert W, Korting H-C. Lipid nanoparticles for improved topical application of drugs for skin diseases. Adv Drug Deliv Rev. 2007; 59(6): 427-43.
44. Essa EA, Bonner MC, Barry BW. Human skin sandwich for assessing shunt route penetration during passive and iontophoretic drug and liposome delivery. J Pharm Pharmacol. 2002; 54(11): 1481-90.
45. Lund W. Principles and practice of pharmaceutics. The Pharmaceutical Codex. 12th ed. London: The Pharmaceutical Press; 1994.
46. Knorr F, Lademann J, Patzelt A, Sterry W, Blume-Peytavi U, Vogt A. Follicular transport route-research progress and future perspectives. Eur J Pharm Biopharm. 2009; 71(2): 173-80.
47. Toll R, Jacobi U, Richter H, Lademann J, Schaefer H, Blume-Peytavi U. Penetration profile of microspheres in follicular targeting of terminal hair follicles. J Invest Dermatol. 2004; 123(1): 168-76.
48. Vogt A, Combadiere B, Hadam S, Stieler KM, Lademann J, Schaefer H, et al. 40 nm, but not 750 or 1, 500 nm, nanoparticles enter epidermal CD1a+ cells after transcutaneous application on human skin. J Invest Dermatol. 2006; 126: 1316-22.
49. Yosipovitch G, Xiong GL, Haus E, Sackett-Lundeen L, Ashkenazi I, Maibach HI. Time-dependent variations of the skin barrier function in humans: transepidermal water loss, stratum corneum hydration, skin surface pH, and skin temperature. J Invest Dermatol. 1998; 110(1): 20-3.